Category: Bayer
-
Bayer Xarelto cases: Denmark becomes interesting patent PI jurisdiction after first Supreme Court clarification of strong validity presumption
The top Danish court also spoke out on the impact of redundant patent claim elements.
-
Bayer adds to COVID patent wars: sues Pfizer/BioNTech, Moderna, J&J over mRNA technologyÂ
Bayer’s Monsanto has sued Pfizer/BioNTech, Moderna, and Johnson & Johnson over the alleged infringement of a patent related to gene sequencing technology through their COVID-19 vaccinations.
-
Munich I Regional Court’s written reasons for multi-country pharma PI: out-of-district defendants can be sued, German procedures apply
The Munich I Regional Court’s headnotes are highly instructive and make the court an attractive forum for cross-border injunctions.
-
Munich I Regional Court’s stunning PI for 20+ countries: based on BSH, doctrine of equivalents, difficult-to-enforce formulation patent
Munich has been a patent injunction hotspot for many years, and the latest development may attract even more litigation to the venue.
-
Federal Circuit partly grants Bayer second chance in defending rivaroxaban patent invalidation campaign
The Federal Circuit has partly affirmed and partly vacated a United States Patent and Trademark Office’s Patent Trial and Appeal Board decision that deemed one of Bayer’s rivaroxaban-related patents invalid, in a three-year case initiated by rivals Mylan Pharmaceuticals, Teva Pharmaceuticals, and Invagen Pharmaceuticals.
-
An interview with Bayer’s outgoing head of IP Dr. Jörg Thomaier, new head Dorian Immler
Following three decades at Bayer, Dr. Jörg Thomaier is retiring as head of IP, super confident that his replacement Dorian Immler will have the energy and drive to make the changes that the department needs to keep prospering.
-
UK wrongful-enforcement damages standard at issue in Sandoz v. Bayer; disclosures in South African patent lawsuits can influence parallel cases
Sandoz is seeking a disgorgement of profits from Bayer, alleging that misrepresentations to the European Patent Office are a basis for going beyond the usual compensation.